The company exhibits extreme negative operating leverage, with quarterly operating losses consistently exceeding $15 million and a net margin of -263.8% as of 2026Q1.
| Sales/Revenue | 38K | 22K | 0 | 1.98M | 3.29M | 2.29M | 394K | 85K |
| Revenue Growth % | - | - | -100% | -39.81% | 43.43% | 481.47% | 363.53% | - |
| Cost of Goods Sold | 2.37M | 3.64M | 0 | 0 | 0 | 0 | 0 | 14.52M |
| COGS % of Revenue | - | 16531.82% | - | - | - | - | - | 17087.06% |
| Gross Profit | -2.33M | -3.62M | 0 | 1.98M | 3.29M | 2.29M | 394K | -14.44M |
| Gross Margin % | -6134.21% | -16431.82% | - | 100% | 100% | 100% | 100% | -16987.06% |
| Gross Profit Growth % | - | - | -100% | -39.81% | 43.43% | 481.47% | 102.73% | - |
| Operating Expenses | 56.5M | 60.11M | 61.04M | 94.7M | 65.37M | 42.74M | 25.09M | 7.39M |
| OpEx % of Revenue | - | 273236.36% | - | 4787.92% | 1989.35% | 1865.43% | 6367.51% | 8696.47% |
| Selling, General & Admin | 24.13M | 26.16M | 23.51M | 34.87M | 37.63M | 21.25M | 9.3M | 7.34M |
| SG&A % of Revenue | - | 118922.73% | - | 1762.79% | 1145.25% | 927.54% | 2361.42% | 8638.82% |
| Research & Development | 33.36M | 37.59M | 34.36M | 32.15M | 28.14M | 21.96M | 15.96M | 14.52M |
| R&D % of Revenue | - | 170845.45% | - | 1625.38% | 856.51% | 958.4% | 4049.75% | 17087.06% |
| Other Operating Expenses | -747K | -3.64M | 3.17M | 27.69M | -408K | -470K | -172K | 0 |
| Operating Income | -58.83M | -63.73M | -61.04M | -92.73M | -62.08M | -40.45M | -24.69M | -21.78M |
| Operating Margin % | -154810.53% | -289668.18% | - | -4687.92% | -1889.35% | -1765.43% | -6267.51% | -25625.88% |
| Operating Income Growth % | - | -4.4% | 34.17% | -49.36% | -53.5% | -63.79% | -13.37% | - |
| EBITDA | -55.09M | -60.09M | -55.19M | -87.3M | -58.16M | -37.44M | -22.71M | -21.36M |
| EBITDA Margin % | -144984.21% | -273136.36% | - | -4413.45% | -1770.05% | -1634.05% | -5763.71% | -25123.53% |
| EBITDA Growth % | 0.33% | -8.88% | 36.78% | -50.09% | -55.37% | -64.85% | -6.34% | - |
| D&A (Non-Cash Add-back) | 3.73M | 3.64M | 5.85M | 5.43M | 3.92M | 3.01M | 1.99M | 427K |
| EBIT | -56.76M | -63.73M | -60.73M | -66.77M | -62.08M | -40.45M | -24.69M | -21.78M |
| Net Interest Income | 634K | 927K | 0 | 2.86M | 1.7M | 11K | 88K | 674K |
| Interest Income | 634K | 927K | 0 | 2.86M | 1.7M | 11K | 88K | 674K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 7.28M | 2.29M | 8.25M | 9.32M | 12.42M | -14.87M | 4.83M | 625K |
| Pretax Income | -51.55M | -61.44M | -52.79M | -83.41M | -49.66M | -55.32M | -19.86M | -21.16M |
| Pretax Margin % | -135650% | -279263.64% | - | -4216.68% | -1511.41% | -2414.62% | -5041.12% | -24890.59% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -51.55M | -61.44M | -52.79M | -71.06M | -58.21M | -55.32M | -19.86M | -21.16M |
| Net Margin % | -135650% | -279263.64% | - | -3592.42% | -1771.45% | -2414.62% | -5041.12% | -24890.59% |
| Net Income Growth % | 5.92% | -16.38% | 25.71% | -22.07% | -5.23% | -178.52% | 6.12% | - |
| Net Income (Continuing) | -51.55M | -61.44M | -52.79M | -83.41M | -49.66M | -55.32M | -19.86M | -21.16M |
| Discontinued Operations | 0 | 0 | 0 | 12.35M | -8.54M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.66 | -2.73 | -11.49 | -20.94 | -13.25 | -12.67 | -4.55 | -15.57 |
| EPS Growth % | 83.95% | 76.24% | 45.13% | -58.04% | -4.58% | -178.46% | 70.78% | - |
| EPS (Basic) | - | -2.73 | -11.49 | -20.94 | -13.25 | -12.67 | -4.55 | -15.57 |
| Diluted Shares Outstanding | 30.97M | 224.83M | 4.6M | 4.44M | 4.39M | 4.37M | 4.37M | 1.36M |
| Basic Shares Outstanding | 30.97M | 224.83M | 4.6M | 4.44M | 4.39M | 4.37M | 4.37M | 1.36M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Imminent liquidity and dilution risk
As reported in recent financial filings, Senti Biosciences generated a nominal $22,000 in TTM revenue, underscoring its status as a pre-commercial entity where top-line figures remain entirely dependent on the timing of non-recurring research collaborations rather than sustainable product sales or recurring commercial market penetration.
The absence of consistent revenue streams suggests that the company is currently in a pure development phase, with financial performance tied to milestone-based partnership agreements. Investors should monitor the conversion of these R&D collaborations into long-term licensing revenue, as current figures provide little insight into future commercial viability.
Based on the provided income statement data, Senti Biosciences maintains a heavy R&D-centric cost structure, with quarterly research expenditures consistently ranging between $5.3 million and $10.5 million, reflecting the intensive capital requirements necessary to advance its proprietary gene circuit platform through early-stage clinical trials.
The company's cost structure is dominated by fixed laboratory overhead and clinical trial execution expenses, which appear to be largely decoupled from revenue generation. This high-burn profile necessitates constant capital market access, as the current expense discipline is insufficient to offset the lack of commercial-scale revenue.
According to historical income statements, Senti Biosciences exhibits extreme negative operating leverage, with quarterly operating losses frequently exceeding $15 million, indicating that the firm has yet to achieve the operational scale required to dilute its fixed R&D and administrative expenses against any meaningful revenue base.
The persistent gap between R&D spending and operating income suggests that the company is prioritizing platform development over near-term profitability. Without a significant shift toward a royalty-based model or successful commercialization, the firm will likely continue to face substantial operating margin pressure as clinical trial costs escalate.
As indicated by the reported $16.4 million cash balance against high quarterly operating losses, Senti Biosciences faces a critical liquidity inflection point that may force significant shareholder dilution or the potential divestiture of core intellectual property assets to sustain ongoing clinical development of its lead programs.
The current cash runway appears insufficient to support long-term clinical validation, raising concerns about the company's ability to reach key value-inflection points without external financing. Investors should be wary of the potential for dilutive equity raises, which may be required to bridge the gap between current operations and future clinical data readouts.
Quick answers to the most common questions about buying SNTI stock.
For fiscal year 2025, Senti Biosciences, Inc. (SNTI) reported total revenue of $0.0M. This represents a 74.1% decline compared to $0.1M in 2019.
Senti Biosciences, Inc. (SNTI) reported a net loss of $61.4M for the fiscal year ending 2025.
Senti Biosciences, Inc. (SNTI) reported an operating income of $-63.7M, resulting in an operating profit margin of -289668.2%. This margin reflects the operational efficiency of the business before interest and taxes.
Senti Biosciences, Inc. (SNTI) generated $-3.6M in gross profit for the year, representing a gross profit margin of -16431.8%. This demonstrates the company's core pricing power and production efficiency.